Literature DB >> 1376311

Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.

Z Debyser1, A M Vandamme, R Pauwels, M Baba, J Desmyter, E De Clercq.   

Abstract

Recently, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione (TIBO) and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) compounds have been shown to be potent, selective, and specific inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in vitro. They interact with the reverse transcriptase of HIV-1 in a way different from that of previously studied reverse transcriptase (RT) inhibitors. We established an endogenous RT assay, starting from intact HIV-1 virions. This assay mimics the reverse transcription process in the HIV-infected cell more closely than RT assays with artificial templates. We investigated the inhibition of endogenous HIV-1 reverse transcription by the TIBO derivative (+)-(S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo [4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione (R-82150) in comparison with the HEPT derivative 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and 2',3'-dideoxyguanosine 5'-triphosphate. The kinetics and characteristics of RT inhibition by TIBO in the endogenous RT assay were similar to those found previously for the exogenous RT assay (following addition of exogenous template/primer); thus, RT inhibition by TIBO was specific for HIV-1 and the extent of RT inhibition was dependent on which of the four substrates (dATP, dTTP, dGTP, and dCTP) was present in limited concentrations. Of the three enzymatic activities, RNA-dependent DNA polymerization was preferentially inhibited, and inhibition was not competitive with respect to the natural substrates. HIV-1 RT behaved as an allosteric enzyme, which means that positive cooperativity for binding of the substrate was observed. TIBO behaved as an allosteric inhibitor by causing a concentration-dependent decrease in this cooperativity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376311

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription.

Authors:  H Zhang; G Dornadula; P Alur; M A Laughlin; R J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.

Authors:  G Maga; D Ubiali; R Salvetti; M Pregnolato; S Spadari
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells.

Authors:  H Zhang; G Dornadula; R J Pomerantz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse Transcriptase.

Authors:  Tatsuro Takahata; Eri Takeda; Minoru Tobiume; Kenzo Tokunaga; Masaru Yokoyama; Yu-Lun Huang; Atsuhiko Hasegawa; Tatsuo Shioda; Hironori Sato; Mari Kannagi; Takao Masuda
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

7.  Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1.

Authors:  Y Quan; Z Gu; X Li; Z Li; C D Morrow; M A Wainberg
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides.

Authors:  Elias G Argyris; Geethanjali Dornadula; Giuseppe Nunnari; Edward Acheampong; Chune Zhang; Ketti Mehlman; Roger J Pomerantz; Hui Zhang
Journal:  Virology       Date:  2006-07-21       Impact factor: 3.616

9.  Inhibition of visna virus replication by 2',3'-dideoxynucleosides and acyclic nucleoside phosphonate analogs.

Authors:  H Thormar; J Balzarini; A Holy; J Jindrich; I Rosenberg; Z Debyser; J Desmyter; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Actinomycin D inhibits human immunodeficiency virus type 1 minus-strand transfer in in vitro and endogenous reverse transcriptase assays.

Authors:  J Guo; T Wu; J Bess; L E Henderson; J G Levin
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.